Sovaprevir
![]() | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| Synonyms | ACH-1625 |
| CAS Number | 1001667-23-7 |
| PubChem (CID) | 53362096 |
| ChemSpider | 28529313 |
| UNII |
2ND9V3MN6O |
| Chemical and physical data | |
| Formula | C43H53N5O8S |
| Molar mass | 799.98 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Sovaprevir (ACH-1625) is an experimental drug designed to treat the hepatitis C virus. It is under development by Achillion Pharmaceuticals.
Sovaprevir received Fast Track status from the U.S. Food and Drug Administration (FDA) in 2012.[1]
References
External links
This article is issued from Wikipedia - version of the 6/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
